FDA elevates OTAT to “Super Office” within CBER
Regulatory NewsJoanne S. Eglovitch.png.aspx?lang=en-us&width=300&height=313&ext=.png)
Biologics/ biosimilars/ vaccinesComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy